What is ONDRISeq?

You are here

What is ONDRISeq?

genomics DNA.JPGONDRISeq is a gene panel that specifically targets neurodegenerative disease genes within the human genome. It was created by the ONDRI genomics team.

How was ONDRISeq created?

Within ONDRI, we hope to better characterize the neurodegenerative processes occurring in the five diseases. Specifically within ONDRI genomics, we’re investigating if there are mutations in each participant’s DNA that may explain the neurodegenerative disease. For example, some mutations can arise in genes that are involved in pathways that aid in the clearance of neurotoxic factors. Participants with mutations in these vital genes can present with neurodegenerative symptoms. We selected genes that are implicated in these biological pathways as well as genes that are known to cause neurodegeneration, when mutated.

What are the goals of using ONDRISeq?

We’re using ONDRISeq to investigate if there are mutations in each ONDRI participant's DNA that may in part explain the neurodegenerative disease the participant is diagnosed with. We’re also investigating whether there are mutations in genes common across all five neurodegenerative diseases.

What progress have you made so far? Have you discovered anything interesting?

We just published the manuscript describing the design of the ONDRISeq gene panel (read it here). To date, we’ve discovered multiple mutations in a number of genes in the patient cohort. However, we’re in the early stages of analyzing the data.

What are the benefits?

Knowledge of the participants’ mutations allows us to know the biological pathways disrupted and possibly, the mechanism of disease. Patients who carry mutations may also be eligible for clinical trials targeting the mutated gene product. If these are clinical trials are available, clinicians can provide this information to eligible patients.

What results do you hope to see?

We hope to learn about the magnitude of neurodegeneration genetic risk carried by each patient. Within ONDRI, we have numerous younger patients (<65 years of age) with severe neurodegenerative symptoms and by studying their genome, we hope to understand the cause of their disease.

Is this a new idea?

The idea of a panel that targets genes associated with a specific disease is not necessarily novel. However, this approach has proven to be useful when studying the genetic basis of other diseases. By integrating genes associated with all five neurodegenerative diseases, we may observe mutations common across the five neurodegenerative diseases.

How will ONDRISeq be used in the future?

By using ONDRISeq, we have demonstrated we can efficiently and economically detect novel as well as known, rare and common mutations in patients’ DNA. Other researchers or clinicians are encouraged to use ONDRISeq to sequence DNA from their neurodegenerative disease patient cohorts.

What stage are you in the patent process?

We successfully completed the ONDRISeq provisional patent application.